Nevertheless, due to its very high tumor accumulation at already 1 h p.i., the chemically identical [18F]F-[natLu]Lu-DOTA-rhCCK-18 might compete with or even surpass the detection rate of currently applied imaging agents for MTC such as 68Ga- or 111In-labeled CCK-2R or SSTR2-targeted compounds and [18F]F-DOPA, which is why a clinical translation of this compound for MTC imaging is recommended. The gene discussed is CCKBR; the disease is neoplasm.